CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
-6.02%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$244M
AUM Growth
+$244M
(-28%)
Cap. Flow
-$79.1M
Cap. Flow
% of AUM
-32.43%
Top 10 Holdings %
Top 10 Hldgs %
68.7%
Holding
38
New
11
Increased
8
Reduced
2
Closed
17
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$20.5M |
| 2 |
AbbVie
ABBV
|
$18.1M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$12.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$12.1M |
| 5 |
Amgen
AMGN
|
$9.93M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$30.1M |
| 2 |
Bristol-Myers Squibb
BMY
|
$29.7M |
| 3 |
Agilent Technologies
A
|
$17.9M |
| 4 |
Legend Biotech
LEGN
|
$15.9M |
| 5 |
Eli Lilly
LLY
|
$15.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-798,137
| Closed | -$6.07M |
|
|
27
Bristol-Myers Squibb
BMY
$96B
| – | – |
-574,057
| Closed | -$29.7M |
|
28
Intellia Therapeutics
NTLA
$1.22B
| – | – |
-390,622
| Closed | -$8.03M |
|
29
Avidity Biosciences
RNA
$5.99B
| – | – |
-160,947
| Closed | -$7.39M |
|
|
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-378,453
| Closed | -$12.1M |
|
31
Enliven Therapeutics
ELVN
$1.2B
| – | – |
-207,896
| Closed | -$5.31M |
|
|
32
Gilead Sciences
GILD
$140B
| – | – |
-359,025
| Closed | -$30.1M |
|
33
Harmony Biosciences
HRMY
$2.12B
| – | – |
-376,315
| Closed | -$15.1M |
|
34
Ionis Pharmaceuticals
IONS
$6.79B
| – | – |
-97,300
| Closed | -$3.9M |
|
35
Iovance Biotherapeutics
IOVA
$807M
| – | – |
-876,009
| Closed | -$8.23M |
|
36
Jazz Pharmaceuticals
JAZZ
$7.75B
| – | – |
-117,500
| Closed | -$13.1M |
|
|
37
Legend Biotech
LEGN
$6.41B
| – | – |
-325,953
| Closed | -$15.9M |
|
|
38
Eli Lilly
LLY
$657B
| – | – |
-17,299
| Closed | -$15.3M |
|